Poor Prognostic Factor with Recalcitrant Conventional Therapy in Moderate to Severe Psoriasis
Keywords:
Psoriasis, Prognostic factor, Conventional therapyAbstract
The Objective of observational prospective study was to identify the poor prognostic factor with recalcitrant conventional therapy in moderate to severe psoriasis. Population was conducted all patients with moderate to severe psoriasis who were started systemic treatment and/or phototherapy for psoriasis, they had never previously received before and regular follow-up at the dermatologic clinic of Sawanpracharak hospital, Nakonsawan between January 2018 and November 2022. This included 152 patients, 87 were non-responder patients, and 65 were responder ones under definition achieving PASI 75. The purposive information was collected data from interviewing of dermatologist. Questionnaires obtains personal information, baseline disease and treatment characteristics. The STATA 16.0 for Windows computer software was used for data processing and statistical analysis. This study was provided risk factors with recalcitrant conventional therapy, Student’s T-test was used for comparison of continuous variables, and categorical variables were analyzed using the Fisher exact test and chi-square. Multivariate analysis by Poisson regression was defined in risk ratio. All statistical tests were conducted at a significance level of 0.05.
The results found that: BMI (risk ratio 3.58, 95% CI 1.01–1.05, p < 0.001) and Psoriatic arthritis (risk ratio 2.04, 95% CI 1.01-1.72, p 0.041) had a significant effect on poor prognostic factors of moderate to severe psoriasis with recalcitrant conventional therapy. Conclusions: BMI and psoriatic arthritis are the poor prognostic factors in recalcitrant conventional therapy in moderate to severe psoriasis which will be considered by selecting other systemic therapy.
References
Al-Janabi, A., & Yiu, Z. Z. N. (2022). Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management. Psoriasis (Auckl), 12, 1-14. doi:10.2147/ptt.S328575
Al-Mutairi, N., & Nour, T. (2014). The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther, 14(6), 749-756. doi:10.1517/14712598.2014.900541
Anghel, F., Nitusca, D., & Cristodor, P. (2021). Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis. Life, 11(12), 1316. Retrieved from https://www.mdpi.com/2075-1729/11/12/1316
Armstrong, A. W. (2017). Psoriasis. JAMA Dermatology, 153(9), 956-956. doi:10.1001/jamadermatol.2017.2103
Aurangabadkar, S. J. (2013). Comorbidities in psoriasis. Indian J Dermatol Venereol Leprol, 79 Suppl 7, S10-17. doi:10.4103/0378-6323.115506
Borsky, P., Chmelarova, M., Fiala, Z., Hamakova, K., Palicka, V., Krejsek, J., . . . Borska, L. (2021). Aging in psoriasis vulgaris: female patients are epigenetically older than healthy controls. Immun Ageing, 18(1), 10. doi:10.1186/s12979-021-00220-5
Brownstone, N. D., Hong, J., Mosca, M., Hadeler, E., Liao, W., Bhutani, T., & Koo, J. (2021). Biologic Treatments of Psoriasis: An Update for the Clinician. Biologics, 15, 39-51. doi:10.2147/btt.S252578
Curmin, R., Guillo, S., De Rycke, Y., Bachelez, H., Beylot-Barry, M., Beneton, N., . . . Tubach, F. (2022). Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. J Eur Acad Dermatol Venereol, 36(11), 2101-2112. doi:10.1111/jdv.18409
Damiani, G., Bragazzi, N. L., Karimkhani Aksut, C., Wu, D., Alicandro, G., McGonagle, D., . . . Naghavi, M. (2021). The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. Front Med (Lausanne), 8, 743180. doi:10.3389/fmed.2021.743180
Edson-Heredia, E., Sterling, K. L., Alatorre, C. I., Cuyun Carter, G., Paczkowski, R., Zarotsky, V., & Maeda-Chubachi, T. (2014). Heterogeneity of response to biologic treatment: perspective for psoriasis. J Invest Dermatol, 134(1), 18-23. doi:10.1038/jid.2013.326
Gisondi, P., Fostini, A. C., Fossà, I., Girolomoni, G., & Targher, G. (2018). Psoriasis and the metabolic syndrome. Clin Dermatol, 36(1), 21-28. doi:10.1016/j.clindermatol.2017.09.005
Jindal, S., & Jindal, N. (2018). Psoriasis and Cardiovascular Diseases: A Literature Review to Determine the Causal Relationship. Cureus, 10(2), e2195. doi:10.7759/cureus.2195
Kamiya, K., Kishimoto, M., Sugai, J., Komine, M., & Ohtsuki, M. (2019). Risk Factors for the Development of Psoriasis. Int J Mol Sci, 20(18). doi:10.3390/ijms20184347
Kunz, M., Simon, J. C., & Saalbach, A. (2019). Psoriasis: Obesity and Fatty Acids. Front Immunol, 10, 1807. doi:10.3389/fimmu.2019.01807
Mekhail, C., Chouk, M., Prati, C., Wendling, D., & Verhoeven, F. (2020). Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review. Expert Rev Clin Pharmacol, 13(5), 505-519. doi:10.1080/17512433.2020.1758556
Menter, A., Gordon, K. B., Leonardi, C. L., Gu, Y., & Goldblum, O. M. (2010). Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol, 63(3), 448-456. doi:10.1016/j.jaad.2009.09.040
Naldi, L. (2016). Psoriasis and smoking: links and risks. Psoriasis (Auckl), 6, 65-71. doi:10.2147/ptt.S85189
Naldi, L., Addis, A., Chimenti, S., Giannetti, A., Picardo, M., Tomino, C., . . . Cuscito, R. (2008). Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology, 217(4), 365-373. doi:10.1159/000156599
Nast, A., Smith, C., Spuls, P. I., Avila Valle, G., Bata-Csörgö, Z., Boonen, H., . . . Dressler, C. (2020). EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol, 34(11), 2461-2498. doi:10.1111/jdv.16915
Nast, A., Smith, C., Spuls, P. I., Avila Valle, G., Bata-Csörgö, Z., Boonen, H., . . . Dressler, C. (2021). EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol, 35(2), 281-317. doi:10.1111/jdv.16926
Ogdie, A., Shin, D. B., Love, T. J., & Gelfand, J. M. (2022). Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study. Rheumatology (Oxford), 61(5), 1877-1884. doi:10.1093/rheumatology/keab622
Pirro, F., Caldarola, G., Chiricozzi, A., Burlando, M., Mariani, M., Parodi, A., . . . De Simone, C. (2021). Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study. Clin Drug Investig, 41(10), 917-925. doi:10.1007/s40261-021-01080-z
Rousset, L., & Halioua, B. (2018). Stress and psoriasis. Int J Dermatol, 57(10), 1165-1172. doi:10.1111/ijd.14032
Sakai, R., Matsui, S., Fukushima, M., Yasuda, H., Miyauchi, H., & Miyachi, Y. (2005). Prognostic factor analysis for plaque psoriasis. Dermatology, 211(2), 103-106. doi:10.1159/000086437
Salah, L. A., Gillstedt, M., & Osmancevic, A. (2016). A Retrospective Study of Patients with Psoriasis Treated with Biologics: Relation to Body Mass Index and Gender. Acta Derm Venereol, 96(7), 974-975. doi:10.2340/00015555-2438
Wu, M. Y., Yu, C. L., Yang, S. J., & Chi, C. C. (2020). Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis. J Am Acad Dermatol, 82(1), 101-109. doi:10.1016/j.jaad.2019.07.103
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Journal of Health Sciences Scholarship
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles, information, images, etc., published in the Journal of Health Sciences Scholarship is the copyright of the Journal of Health Sciences Scholarship. If any person or entity wants to bring all or part of it to publish or to do any action must be authorized by a letter from the Journal of Health Sciences Scholarship. The content and information in the article published in the Journal of Health Sciences Scholarship is considered and the responsibility of the author of the article directly, which editorial journals, no need to agree or share any responsibility.
Messages and Comments The author of the article. This is not the opinion of the journal, and the journal does not need to agree with the text and any comments of the author. The magazine reserves the right to consider publication as appropriate include the correct or refine the language to meet the criteria.
